<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE HTML>
<html xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" lang="en">
  <head>
    <meta http-equiv="Content-Type" content="text/html;charset=utf-8"/>
    <title>Ibrance (palbociclib) tablets - THIS DOCUMENT IS FOR TESTING PURPOSES ONLY. (Bundle) - Gravitate Health FHIR Implementation Guide v0.1.0</title>

    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
    <meta name="author" content="http://hl7.org/fhir"/>

    <link rel="stylesheet" href="fhir.css"/>

      <!-- Bootstrap core CSS -->
    <link rel="stylesheet" href="assets/css/bootstrap-fhir.css"/>

      <!-- Project extras -->
    <link rel="stylesheet" href="assets/css/project.css"/>
    <link rel="stylesheet" href="assets/css/pygments-manni.css"/>
    <link rel="stylesheet" href="assets/css/jquery-ui.css"/>
  	<link rel="stylesheet" href="assets/css/prism.css"/>
      <!-- Placeholder for child template CSS declarations -->
    <link rel="stylesheet" href="assets/css/pcsp.css"/>
    <link rel="stylesheet" href="assets/css/epi.css"/>

    <script src="fhir-table-scripts.js" type="text/javascript"> </script>

      <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
      <!-- [if lt IE 9]>
    <script src="assets/js/html5shiv.js"></script>
    <script src="assets/js/respond.min.js"></script>
    <![endif] -->

      <!-- Favicons -->
    <link sizes="144x144" rel="fhir-logo" href="assets/ico/icon-fhir-144.png"/>
    <link sizes="114x114" rel="fhir-logo" href="assets/ico/icon-fhir-114.png"/>
    <link sizes="72x72" rel="fhir-logo" href="assets/ico/icon-fhir-72.png"/>
    <link rel="fhir-logo" href="assets/ico/icon-fhir-57.png"/>
    <link rel="shortcut icon" href="assets/ico/favicon.png"/>
  </head>
  <body onload="document.body.style.opacity='1'">

	  <script src="assets/js/prism.js"></script>

    <style type="text/css">h2{--heading-prefix:"16.593"}
    h3,h4,h5,h6{--heading-prefix:"16.593"}</style>
    <div id="segment-header" class="segment">    <!-- segment-header -->
      <div class="container">    <!-- container -->
        
        <div id="hl7-nav">
          <a no-external="true" id="hl7-logo" href="https://www.gravitatehealth.eu/">
            <img src="assets/images/logo-header.jpg" alt="Visit the Project website" height="60"/>
          </a>
        </div>
   <!-- <div id="family-nav">
          <a id="family-logo" no-external="true" href="https://www.pancare.eu/projects"><img height="40" alt="Visit the PanCareSurPass website" src="assets/images/who-logo-www.jpg"/> </a>
        </div> -->
        <div id="hl7-search">
          <a no-external="true" id="hl7-search-lnk" href="http://hl7.org/fhir/search.cfm"><img src="assets/images/search.png" alt="Search FHIR"/></a>
        </div>


        <div id="ig-status">
          <p><span style="font-size:12pt;font-weight:bold">Gravitate Health FHIR Implementation Guide</span>
            <br/>
            <span style="display:inline-block;">0.1.0 - CI Build


            </span>
          </p>
        </div>
      </div>   <!-- /container -->
    </div>    <!-- /segment-header -->

    <div id="segment-navbar" class="segment">    <!-- segment-navbar -->
      <div id="stripe"> </div>
      <div class="container">    <!-- container -->
          <!-- HEADER CONTENT -->

        <nav class="navbar navbar-inverse">
            <!-- status-bar -->
          <div class="container">
            <button data-target=".navbar-inverse-collapse" data-toggle="collapse" type="button" class="navbar-toggle">
              <span class="icon-bar"> </span>
              <span class="icon-bar"> </span>
              <span class="icon-bar"> </span>
            </button>
            <a href="http://hl7.org/fhir/R5/index.html" class="navbar-brand hidden">FHIR</a>
            <div class="nav-collapse collapse navbar-inverse-collapse">
                <!-- menu.xml -->

<ul class="nav navbar-nav">
  <li>
    <a href="toc.html">Table of Contents</a>
  </li>
  <li class="dropdown">
    <a data-toggle="dropdown" href="#" class="dropdown-toggle">Introduction
      <b class="caret"></b>
    </a>
    <ul class="dropdown-menu">
      <li>
        <a href="index.html">Overview</a>
      </li>
      <li>
        <a href="01-1-functional-analysis.html">Functional Analysis</a>
      </li>
    </ul>
  </li>
  <li class="dropdown">
    <a data-toggle="dropdown" href="#" class="dropdown-toggle">ePI Processing
      <b class="caret"></b>
    </a>
    <ul class="dropdown-menu">
      <li>
        <a href="09-epi-processing.html">Epi Processing</a>
      </li>
      <li>
        <a href="10-semantic-annotation.html">Semantic Annotation</a>
      </li>
      <li>
        <a href="08-persona-dimensions.html">Persona Dimensions</a>
      </li>
      <li>
        <a href="11-ips-considerations.html">IPS Considerations</a>
      </li>
      <li>
        <a href="12-operations.html">Operations</a>
      </li>
      <li>
        <a href="03-terminology.html">Terminology</a>
      </li>
    </ul>
  </li>
  <li class="dropdown">
    <a data-toggle="dropdown" href="#" class="dropdown-toggle">Cross Cooperation
      <b class="caret"></b>
    </a>
    <ul class="dropdown-menu">
      <li>
        <a href="13-international-coop.html">International</a>
      </li>
      <li>
        <a href="13-1-project-coop.html">Project</a>
      </li>
    </ul>
  </li>
  <li>
    <a href="05-capability.html">Capability</a>
  </li>
  <li>
    <a href="06-general-technical-conformance-requirements.html">Technical Requirements</a>
  </li>
  <li>
    <a href="artifacts.html">Artifact Index</a>
  </li>
</ul>
            </div>    <!-- /.nav-collapse -->
          </div>    <!-- /.container -->
        </nav>    <!-- /.navbar -->
        <!-- /HEADER CONTENT -->
      </div>    <!-- /container -->
    </div>    <!-- /segment-navbar -->
      <!-- status-bar -->

    <div id="segment-breadcrumb" class="segment">    <!-- segment-breadcrumb -->
      <div class="container">    <!-- container -->
        <ul class="breadcrumb">
          <li><a href="toc.html"><b>Table of Contents</b></a></li><li><a href="artifacts.html"><b>Artifacts Summary</b></a></li><li><b>Ibrance (palbociclib) tablets - THIS DOCUMENT IS FOR TESTING PURPOSES ONLY. (Bundle)</b></li>

        </ul>
      </div>    <!-- /container -->
    </div>    <!-- /segment-breadcrumb -->

    <a name="top"> </a>
    <div id="segment-content" class="segment">    <!-- segment-content -->
      <div class="container">    <!-- container -->
        <div class="row">
          <div class="inner-wrapper">

<div class="col-12">
    <!-- ReleaseHeader --><p id="publish-box">Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7&reg; FHIR&reg; Standard) CI Build. This version is based on the current content of <a href="https://github.com/hl7-eu/gravitate-health">https://github.com/hl7-eu/gravitate-health</a> and changes regularly. See the <a href="http://hl7.eu/fhir/ig/gravitate-health/history.html">Directory of published versions</a></p>  <!-- EndReleaseHeader -->

  








<ul class="nav nav-tabs">

  <li class="active">
    <a href="#">Narrative Content</a>
  </li>



  
    <li>
      <a href="Bundle-bundle-ibrance75-100-125.xml.html">XML</a>
    </li>
  


  
    <li>
      <a href="Bundle-bundle-ibrance75-100-125.json.html">JSON</a>
    </li>
  


  
    <li>
      <a href="Bundle-bundle-ibrance75-100-125.ttl.html">TTL</a>
    </li>
  



</ul>


  <a name="root"> </a>


  <h2 id="root">Bundle: Ibrance (palbociclib) tablets - THIS DOCUMENT IS FOR TESTING PURPOSES ONLY. (Bundle)</h2>





   
   
  

  




<div>
  
  <b>Composition category:</b>
  
  <br/>
  
    <b>Composition status:</b>
    final
  <br/>
  
    <b>Composition type:</b>
    HUMAN PRESCRIPTION LABEL
  <br/>
  

  <h2>Narrative Text</h2>
  <br/>

  
    <h3>SPL PATIENT PACKAGE INSERT SECTION</h3>
    <p>
      </p>
    
      

        <h4>PATIENT INFORMATION</h4>
        <p>
          <div>
								<b>
									IBRANCE <sup>&reg;</sup> (EYE-brans) <br/> (palbociclib)
								</b>
								<br/> Tablets
							</div></p>

      

        <h4>What is the most important information I should know about IBRANCE?</h4>
        <p>
          <div>
								<p>
									<b>IBRANCE may cause serious side effects, including:</b>
								</p>
								<p>
									<b>Low white blood cell counts (neutropenia).</b> Low white
									blood cell counts are very common when taking IBRANCE and may
									cause serious infections that can lead to death. Your healthcare
									provider should check your white blood cell counts before and
									during treatment.
								</p>
								<p>
									If you develop low white blood cell counts during treatment with
									IBRANCE, your healthcare provider may stop your treatment,
									decrease your dose, or may tell you to wait to begin your
									treatment cycle. Tell your healthcare provider right away if you
									have signs and symptoms of low white blood cell counts or
									infections such as fever and chills.
								</p>
								<p>
									<b>Lung problems (pneumonitis).</b> IBRANCE may cause severe or
									life-threatening inflammation of the lungs during treatment that
									can lead to death. Tell your healthcare provider right away if
									you have any new or worsening symptoms, including:
								</p>
								<ul>
									<li>chest pain</li>
									<li>cough with or without mucus</li>
									<li>trouble breathing or shortness of breath</li>
								</ul>
								<p>
									Your healthcare provider may interrupt or stop treatment with
									IBRANCE completely if your symptoms are severe.
								</p>
								<p>
									<b><a name="l466">​</a>
										See <a href="#UUID-NESTED-SECTION-6">
											"What are the possible side effects of
											IBRANCE?"
										</a> for more information about side effects.
									</b>
								</p>
							</div></p>

      

        <h4>What is IBRANCE?</h4>
        <p>
          <div>
								<p>
									IBRANCE is a prescription medicine used in adults to treat
									hormone receptor (HR)-positive, human epidermal growth factor
									receptor 2 (HER2)-negative breast cancer that has spread to
									other parts of the body (metastatic) in combination with:
								</p>
								<ul>
									<li>
										an aromatase inhibitor as the first hormonal based therapy
										in postmenopausal women or in men, or
									</li>
									<li>
										fulvestrant in people with disease progression following
										hormonal therapy.
									</li>
								</ul>
								<p>
									It is not known if IBRANCE is safe and effective in children.
								</p>
							</div></p>

      

        <h4>Before taking IBRANCE, tell your healthcare provider about all of your medical conditions, including if you:</h4>
        <p>
          <div>
								<ul>
									<li>
										have fever, chills, or any other signs or symptoms of
										infection.
									</li>
									<li>have liver or kidney problems.</li>
									<li>
										are pregnant, or plan to become pregnant. IBRANCE can harm
										your unborn baby.
									</li>
									<li>
										<ul>
											<li>
												Females who are able to become pregnant should use
												effective birth control during treatment and for at
												least 3 weeks after the last dose of IBRANCE. Your
												healthcare provider may ask you to take a pregnancy
												test before you start treatment with IBRANCE.
											</li>
											<li>
												Males with female partners who can become pregnant
												should use effective birth control during treatment
												with IBRANCE for at least 3 months after the last
												dose of IBRANCE.
											</li>
											<li>
												Talk to your healthcare provider about birth control
												methods that may be right for you during this
												time.
											</li>
											<li>
												If you become pregnant or think you are pregnant,
												tell your healthcare provider right away.
											</li>
										</ul>
									</li>
									<li>
										are breastfeeding or plan to breastfeed. It is not known if
										IBRANCE passes into your breast milk. Do not breastfeed
										during treatment with IBRANCE and for 3 weeks after the last
										dose.
									</li>
								</ul>
								<p>
									<b>
										Tell your healthcare provider about all of the medicines you
										take, including
									</b> prescription and over-the-counter
									medicines, vitamins, and herbal supplements. IBRANCE and other
									medicines may affect each other causing side effects.
								</p>
							</div></p>

      

        <h4>How should I take IBRANCE?</h4>
        <p>
          <div>
								<ul>
									<li>
										Take IBRANCE exactly as your healthcare provider tells
										you.
									</li>
									<li>IBRANCE tablets may be taken with or without food.</li>
									<li>
										IBRANCE should be taken at about the same time each
										day.
									</li>
									<li>
										Swallow IBRANCE tablets whole. Do not chew, crush or split
										IBRANCE tablets before swallowing them.
									</li>
									<li>
										Do not take any IBRANCE tablets that are broken, cracked, or
										that look damaged.
									</li>
									<li>
										Avoid grapefruit and grapefruit products during treatment
										with IBRANCE. Grapefruit may increase the amount of IBRANCE
										in your blood.
									</li>
									<li>
										Do not change your dose or stop taking IBRANCE unless your
										healthcare provider tells you.
									</li>
									<li>
										If you miss a dose of IBRANCE or vomit after taking a dose
										of IBRANCE, do not take another dose on that day. Take your
										next dose at your regular time.
									</li>
									<li>
										If you take too much IBRANCE, call your healthcare provider
										right away or go to the nearest hospital emergency
										room.
									</li>
								</ul>
							</div></p>

      

        <h4>What are the possible side effects of IBRANCE?</h4>
        <p>
          <div>
								<p>
									<b><a name="l591">​</a>
										IBRANCE may cause serious side effects. See <a href="#UUID-NESTED-SECTION-2">
											"What is the most important information I should know about IBRANCE?"
										</a>
									</b>
								</p>
								<p>
									<b>
										The most common side effects of IBRANCE when used with either
										letrozole or fulvestrant include:
									</b>
								</p>
								<ul>
									<li>
										Low red blood cell counts and low platelet counts are
										common with IBRANCE. Call your healthcare provider right
										away if you develop any of these symptoms during treatment: <ul>
											<li>dizziness</li>
											<li>shortness of breath</li>
											<li>weakness</li>
											<li>bleeding or bruising more easily</li>
											<li>nosebleeds</li>
										</ul>
									</li>
									<li><a name="l627">​</a>
										infections (see <a href="#UUID-NESTED-SECTION-2">
											"What is the most important
											information I should know about IBRANCE?
										</a>")
									</li>
									<li>tiredness</li>
									<li>nausea</li>
									<li>sore mouth</li>
									<li>abnormalities in liver blood tests</li>
									<li>diarrhea</li>
									<li>hair thinning or hair loss</li>
									<li>vomiting</li>
									<li>rash</li>
									<li>loss of appetite</li>
								</ul>
								<p>
									IBRANCE may cause fertility problems in males. This may affect
									your ability to father a child. Talk to your healthcare provider
									about family planning options before starting IBRANCE if this is
									a concern for you.
								</p>
								<p> These are not all of the possible side effects of IBRANCE. </p>
								<p>
									Call your doctor for medical advice about side effects. You may
									report side effects to FDA at 1-800-FDA-1088.
								</p>
							</div></p>

      

        <h4>How should I store IBRANCE?</h4>
        <p>
          <div>
								<ul>
									<li>
										Store IBRANCE at 68 °F to 77 °F (20 °C to 25 °C) in the
										original blister pack.
									</li>
								</ul>

								<p>
									<b>
										Keep IBRANCE and all medicines out of the reach of
										children.
									</b>
								</p>
							</div></p>

      

        <h4>General information about the safe and effective use of IBRANCE</h4>
        <p>
          <div>
								<p>
									Medicines are sometimes prescribed for purposes other than those
									listed in a Patient Information leaflet. Do not use IBRANCE for
									a condition for which it was not prescribed. Do not give IBRANCE
									to other people, even if they have the same symptoms you have.
									It may harm them. You can ask your pharmacist or healthcare
									provider for more information about IBRANCE that is written for
									health professionals.
								</p>
							</div></p>

      

        <h4>What are the ingredients in IBRANCE?</h4>
        <p>
          <div>
								<p> Active ingredient: palbociclib </p>
								<p>
									Inactive ingredients: microcrystalline cellulose, colloidal
									silicon dioxide, crospovidone, magnesium stearate, succinic
									acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and
									FD&amp;C Blue #2/Indigo Carmine Aluminum Lake. In addition, the
									75 mg and 125 mg tablets contain red iron oxide and the 100 mg
									tablets contain yellow iron oxide.
								</p>
								<p><a name="l715">​</a>
									<img src="#UUID-IBRANCE-05" alt="Pfizer Logo"/>
								</p>
								<p> LAB-1372-1.0 </p>
								<p>
									For more information, go to www.IBRANCE.com or call
									1-800-438-1985.
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - TOPPER CARD</h4>
        <p>
          <div>
								<p>Your Monthly Box</p>
								<p>Includes 3 weekly packs of&nbsp;</p>
								<p>IBRANCE&reg;&nbsp;(palbociclib) medication.</p>
								<p>Fill in the dates below to help track your treatment cycle.</p>
								<p>Treatment Cycle</p>
								<p>Week 1&nbsp;&nbsp;&nbsp;Week 2&nbsp;&nbsp;&nbsp;Week 3</p>
								<p>IBRANCE</p>
								<p>Week 4</p>
								<p>No IBRANCE</p>
								<p>My Treatment Cycle Tracker</p>
								<p>I start my Week 1&nbsp;</p>
								<p>treatment cycle on:&nbsp;</p>
								<p>________ / ______</p>
								<p>MONTH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DAY</p>
								<p>After Week 4, I will start my</p>
								<p>next treatment cycle on:</p>
								<p>________ / ______</p>
								<p>MONTH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DAY</p>
								<p>PAA119239</p>
								<p><a name="l791">​</a>
									<img src="#UUID-IBRANCE-07" alt="TOPPER CARD"/>
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - 75 MG TABLET DOSE PACK</h4>
        <p>
          <div>
								<p>Pfizer</p>
								<p>NDC 0069-0284-07</p>
								<p>IBRANCE&reg;&nbsp;</p>
								<p>(palbociclib)</p>
								<p>tablets</p>
								<p>75 mg per tablet</p>
								<p>This weekly pack contains:</p>
								<p>7 tablets</p>
								<p>Rx only</p>
								<p><a name="l831">​</a>
									<img src="#UUID-IBRANCE-08" alt="75 MG TABLET DOSE PACK"/>
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - 75 MG TABLET DOSE PACK CARTON</h4>
        <p>
          <div>
								<p>Pfizer</p>
								<p>NDC 0069-0284-03</p>
								<p>IBRANCE&reg;&nbsp;</p>
								<p>(palbociclib)</p>
								<p>tablets</p>
								<p>75 mg</p>
								<p>21 tablets</p>
								<p>Monthly Box Contains: 3 individual weekly</p>
								<p>packs. Each pack contains 7 IBRANCE tablets</p>
								<p>(75 mg per tablet).</p>
								<p>Rx only</p>
								<p>Safety</p>
								<p>Label</p>
								<p><a name="l883">​</a>
									<img src="#UUID-IBRANCE-09" alt="75 MG TABLET DOSE PACK CARTON"/>
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - 100 MG TABLET DOSE PACK</h4>
        <p>
          <div>
								<p>Pfizer</p>
								<p>NDC 0069-0486-07</p>
								<p>IBRANCE&reg;&nbsp;</p>
								<p>(palbociclib)</p>
								<p>tablets</p>
								<p>100 mg per tablet</p>
								<p>This weekly pack contains:</p>
								<p>7 tablets</p>
								<p>Rx only</p>
								<p><a name="l923">​</a>
									<img src="#UUID-IBRANCE-10" alt="100 MG TABLET DOSE PACK"/>
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - 100 MG TABLET DOSE PACK CARTON</h4>
        <p>
          <div>
								<p>Pfizer</p>
								<p>NDC 0069-0486-03</p>
								<p>IBRANCE&reg;&nbsp;</p>
								<p>(palbociclib)</p>
								<p>tablets</p>
								<p>100 mg</p>
								<p>21 tablets</p>
								<p>Monthly Box Contains: 3 individual weekly</p>
								<p>packs. Each pack contains 7 IBRANCE tablets</p>
								<p>(100 mg per tablet).</p>
								<p>Rx only</p>
								<p>Safety</p>
								<p>Label</p>
								<p><a name="l975">​</a>
									<img src="#UUID-IBRANCE-11" alt="100 MG TABLET DOSE PACK CARTON"/>
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - 125 MG TABLET DOSE PACK</h4>
        <p>
          <div>
								<p>Pfizer</p>
								<p>NDC 0069-0688-07</p>
								<p>IBRANCE&reg;&nbsp;</p>
								<p>(palbociclib)</p>
								<p>tablets</p>
								<p>125 mg per tablet</p>
								<p>This weekly pack contains:</p>
								<p>7 tablets</p>
								<p>Rx only</p>
								<p><a name="l1015">​</a>
									<img src="#UUID-IBRANCE-12" alt="125 MG TABLET DOSE PACK"/>
								</p>
							</div></p>

      

        <h4>PRINCIPAL DISPLAY PANEL - 125 MG TABLET DOSE PACK CARTON</h4>
        <p>
          <div>
								<p>Pfizer</p>
								<p>NDC 0069-0688-03</p>
								<p>IBRANCE&reg;&nbsp;</p>
								<p>(palbociclib)</p>
								<p>tablets</p>
								<p>125 mg</p>
								<p>21 tablets</p>
								<p>Monthly Box Contains: 3 individual weekly</p>
								<p>packs. Each pack contains 7 IBRANCE tablets</p>
								<p>(125 mg per tablet).</p>
								<p>Rx only</p>
								<p>Safety</p>
								<p>Label</p>
								<p><a name="l1067">​</a>
									<img src="#UUID-IBRANCE-13" alt="125 MG TABLET DOSE PACK CARTON"/>
								</p>
							</div></p>

      
    
  

</div>


<h2>Product Information</h2>




  <div class="container rcorners mpd">
  
  <h4>
    IBRANCE&reg; (palbociclib) tablets - 75 mg
  </h4>

  
  
    NDC:
    <b>
      0069-0284
    </b>
    
  
  <hr/></div></div></div></div></div></div></body></html>